Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

Journal Articles

Synthetic Pentasaccharide Fondaparinux (Arixtra ® ) Reduces Sepsis Induced Coagulopathy and Promotes Survival in the Baboon Model of E. coli Sepsis

Ravi Shankar Keshari, PhD, Robert Silasi, PhD, Narcis Ioan Popescu, PhD, Cristina Lupu, PhD, Charles Esmon, PhD, Florea Lupu, PhD

Blood (2017) 130 (Supplement 1): 2375.

https://doi.org/10.1182/blood.V130.Suppl_1.2375.2375

Published: 2017

Journal Articles

Fixed Doses of Anticoagulants Cause Wide Variation of Thrombin Generation

Coenraad Hemker, MD PhD, Saartje Bloemen, PhD, Romy Kremers, PhD, Hilde Kelchtermans, PhD, Bas De Laat, MD PhD

Blood (2016) 128 (22): 5012.

https://doi.org/10.1182/blood.V128.22.5012.5012

Published: 2016

Journal Articles

Distinct Mechanism of Anti-Hemophilic FVIII Activation By Nascent FXa in the Tissue Factor-FVIIa Coagulation Initiation Complex Resistant to FXa-Directed Inhibition

Yuichi Kamikubo, PhD, Grazia Loredana Mendolicchio, MD PhD, Antonella Zampolli, PhD, Patrizia Marchese, PhD, Andrew J. Gale, PhD, Sriram Krishnaswamy, PhD, Andras Gruber, MD, Lars Christian Petersen, Wolfram Ruf, MD, Zaverio M Ruggeri, MD

Blood (2014) 124 (21): 2803.

https://doi.org/10.1182/blood.V124.21.2803.2803

Published: 2014

Journal Articles

Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT)

Zheng Cai, PhD, Serge V. Yarovoi, PhD, Zhiquiang Zhu, PhD, Lubica Rauova, MD,PhD, Tatiana Lebedeva, PhD, Mortimer Poncz, MD, Gowthami M Arepally, MD, Douglas B. Cines, MD, Mark I. Greene, MD

Blood (2014) 124 (21): 465.

https://doi.org/10.1182/blood.V124.21.465.465

Published: 2014

Journal Articles

Relieving Inhibition of Prothrombinase By TFPIα: a Procoagulant Activity of Unfractionated, Low Molecular Weight, and Nonanticoagulant Heparins

Jeremy P Wood, PhD, Lisa M Baumann Kreuziger, MD, Rodney M. Camire, PhD, Umesh R Desai, PhD, Alan E. Mast, MD PhD

Blood (2014) 124 (21): 1478.

https://doi.org/10.1182/blood.V124.21.1478.1478

Published: 2014

Journal Articles

Size matters

Andras Gruber, Erik I. Tucker

Blood (2011) 118 (25): 6481–6482.

https://doi.org/10.1182/blood-2011-10-382622

Published: 2011

Journal Articles

A Novel Polymer Based Antidote for Reversing the Anticoagulation Effect of Clinically Used Heparins,

Rajesh A Shenoi, PhD, Benjamin F L Lai, MSc, Dirk Lange, PhD, Donald E Brooks, PhD, Ben Chew, MD, Cedric John Carter, MD, Jayachandran N Kizhakkedathu, PhD

Blood (2011) 118 (21): 3359.

https://doi.org/10.1182/blood.V118.21.3359.3359

Published: 2011

Journal Articles

Comparative Studies on the HIT Antibody Mediated Platelet Aggregation / Serotonin Release by Synthetic Pentasaccharide and Two Chemoenzymatically Synthesized Heptasaccharides

Jeanine M. Walenga, PhD, Chris Aranda, Robert Linhardt, Jian Liu, Mary Lewis, Debra Hoppensteadt, Ph.D., Jawed Fareed, PhD

Blood (2011) 118 (21): 2231.

https://doi.org/10.1182/blood.V118.21.2231.2231

Published: 2011

Journal Articles

Probing Anticoagulant Fondaparinux for Interference with Prothrombotic B2GPI/Anti-B2GPI Antibody Complexes

Alexey Kolyada, Alfredo De Biasio, Natalia Beglova

Blood (2011) 118 (21): 1209.

https://doi.org/10.1182/blood.V118.21.1209.1209

Published: 2011

Journal Articles

Reversal of Heparin by Novel Synthetic Antagonist PMX-60056 Exhibits a Linear Dose-Response Relationship

R. Eric McAllister, MD, DPhil

Blood (2010) 116 (21): 3329.

https://doi.org/10.1182/blood.V116.21.3329.3329

Published: 2010

Journal Articles

Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism In Acutely Ill Medical Patients: MAGELLAN Study Methodology

Alexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, Lloyd Haskell, Da-Yi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alexander Spyropoulos, Victor Tapson

Blood (2010) 116 (21): 3331.

https://doi.org/10.1182/blood.V116.21.3331.3331

Published: 2010

Journal Articles

Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs

Grigoris T Gerotziafas, Mouna Sassi, Vassiliki Galea, Jawed Fareed, PhD, Jeanine M. Walenga, PhD, Ismail Elalamy

Blood (2010) 116 (21): 3334.

https://doi.org/10.1182/blood.V116.21.3334.3334

Published: 2010

Journal Articles

Protein Inhibitor of Coagulation Factor Xa (PifXa): A New Protein-Based Specific Factor Xa Inhibitor Is An Effective, Reversible Inhibitor of Blood Coagulation.

Mette Sondrup Andersen, Aage Kristian Olsen Alstrup, Julie Kirstine Andersen, Søren Risom Kristensen, Kåre Lehmann Nielsen

Blood (2010) 116 (21): 1095.

https://doi.org/10.1182/blood.V116.21.1095.1095

Published: 2010

Journal Articles

Arylamides: Discovery of a Novel Class of Fully-Synthetic Small Molecule Heparin and LMWH Antagonists.

Richard W. Scott, Ph.D., Michael J. Costanzo, Ph.D., Katie B. Freeman, Ph.D., Robert W. Kavash, Ph.D., Trevor M. Young, William F. DeGrado, Ph.D., Walter Jeske, Ph.D.

Blood (2010) 116 (21): 1096.

https://doi.org/10.1182/blood.V116.21.1096.1096

Published: 2010

Journal Articles

Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma.

Grigoris T Gerotziafas, Tahar Chakroun, Vassiliki Galea, Meyer Michel Samama, MD, Ismail Elalamy

Blood (2010) 116 (21): 1106.

https://doi.org/10.1182/blood.V116.21.1106.1106

Published: 2010

Journal Articles

Differential Effects of Heparins on the Nanostructure of Fibrin Clot.

Francois Caton, PhD, Christelle Yeromonahos, MSc, Raphael Marlu, MD, Benoit Polack, MD, PhD

Blood (2010) 116 (21): 1155.

https://doi.org/10.1182/blood.V116.21.1155.1155

Published: 2010

Journal Articles

Optimized Fully-Synthetic Salicylamide Heparin Antagonists Have Greater Efficacy Versus LMWHs and Display Improved Hemodynamic Responses as Compared to Protamine

Richard W. Scott, Ph.D., Michael J. Costanzo, Ph.D., Katie B. Freeman, Ph.D., Robert W. Kavash, Ph.D., Trevor M. Young, William F. DeGrado, Ph.D., Walter Jeske, Ph.D.

Blood (2010) 116 (21): 191.

https://doi.org/10.1182/blood.V116.21.191.191

Published: 2010

Journal Articles

Fondaparinux for the Treatment of Recurrent Venous Thromboembolism During Low Molecular Weight Heparin Therapy: A Retrospective Case Series.

Rashmi Ramasubbaiah, MD, MS, Patrick J Kiel, PharmD, Rakesh Mehta, MD, Anne Greist, MD, Kellie L Jones, PharmD

Blood (2009) 114 (22): 4179.

https://doi.org/10.1182/blood.V114.22.4179.4179

Published: 2009

Journal Articles

In Vitro Characteristics of Fondaparinux On HIT/HITT Samples.

Nadia N Gould, Christine L Haley, Lu Song, PhD, Mervyn A. Sahud, MD, Jeffrey Dlott, MD

Blood (2009) 114 (22): 1319.

https://doi.org/10.1182/blood.V114.22.1319.1319

Published: 2009

NARROW

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Synthetic Pentasaccharide Fondaparinux (Arixtra ® ) Reduces Sepsis Induced Coagulopathy and Promotes Survival in the Baboon Model of E. coli Sepsis

Fixed Doses of Anticoagulants Cause Wide Variation of Thrombin Generation

Distinct Mechanism of Anti-Hemophilic FVIII Activation By Nascent FXa in the Tissue Factor-FVIIa Coagulation Initiation Complex Resistant to FXa-Directed Inhibition

Atomic Level Description of the Immune Complex That Causes Heparin-Induced Thrombocytopenia (HIT)

Relieving Inhibition of Prothrombinase By TFPIα: a Procoagulant Activity of Unfractionated, Low Molecular Weight, and Nonanticoagulant Heparins

Size matters

A Novel Polymer Based Antidote for Reversing the Anticoagulation Effect of Clinically Used Heparins,

Comparative Studies on the HIT Antibody Mediated Platelet Aggregation / Serotonin Release by Synthetic Pentasaccharide and Two Chemoenzymatically Synthesized Heptasaccharides

Probing Anticoagulant Fondaparinux for Interference with Prothrombotic B2GPI/Anti-B2GPI Antibody Complexes

Reversal of Heparin by Novel Synthetic Antagonist PMX-60056 Exhibits a Linear Dose-Response Relationship

Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism In Acutely Ill Medical Patients: MAGELLAN Study Methodology

Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs

Protein Inhibitor of Coagulation Factor Xa (PifXa): A New Protein-Based Specific Factor Xa Inhibitor Is An Effective, Reversible Inhibitor of Blood Coagulation.

Arylamides: Discovery of a Novel Class of Fully-Synthetic Small Molecule Heparin and LMWH Antagonists.

Structural Determinants of Enoxaparin Oligosaccharides for the Down-Regulation of Tissue Factor Induced Factor VIIa Generation In Human Plasma.

Differential Effects of Heparins on the Nanostructure of Fibrin Clot.

Optimized Fully-Synthetic Salicylamide Heparin Antagonists Have Greater Efficacy Versus LMWHs and Display Improved Hemodynamic Responses as Compared to Protamine

Fondaparinux for the Treatment of Recurrent Venous Thromboembolism During Low Molecular Weight Heparin Therapy: A Retrospective Case Series.

In Vitro Characteristics of Fondaparinux On HIT/HITT Samples.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only